Neogen Corporation — Form 10-Q Summary
Business context and reporting period: Neogen develops and sells food-safety diagnostic products and animal-safety products and services. This unaudited filing covers the first quarter of fiscal 2013, the three months ended August 31, 2012, compared with the three months ended August 31, 2011. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
Financial performance and position
| Metric | Q1 FY2013 | Q1 FY2012 | Change |
|---|---|---|---|
| Net sales | $49.729 million | $45.697 million | +8.8% |
| Gross margin | $26.494 million; 53.3% | $22.977 million; 50.3% | Margin +3.0 percentage points |
| Operating expenses | $16.166 million | $13.627 million | +18.6% |
| Operating income | $10.328 million; 20.8% margin | $9.350 million; 20.5% margin | +10.5% |
| Net income attributable to Neogen | $6.714 million | $6.004 million | +11.8% |
| EPS attributable to Neogen | $0.28 basic and diluted | $0.26 basic; $0.25 diluted | Higher year over year |
| Operating cash flow | $4.444 million | $1.347 million | Increased |
Food Safety sales rose 12.5% to $26.195 million; Animal Safety sales rose 5.0% to $23.534 million. International markets represented 41.7% of revenue, versus 41.4% a year earlier. Management reported organic company revenue growth of 8.1%; the balance of reported growth reflected the May 2012 Igenity acquisition.
At August 31, 2012, cash and cash equivalents were $44.485 million and marketable securities were $30.019 million, totaling $74.504 million, compared with $68.645 million at May 31, 2012. Current assets were $152.735 million and current liabilities were $18.970 million. Total liabilities were $31.582 million and equity was $229.215 million. There was no outstanding borrowing under the $12 million revolving credit line; it was extended to September 1, 2014. The company reported compliance with its financial covenants.
Investing activities used $12.342 million, principally reflecting net purchases of marketable securities; capital expenditures and other asset purchases were $1.923 million. Financing provided $3.236 million, including $2.494 million in net proceeds from stock issuance and options. Cash declined by $4.560 million during the quarter to $44.485 million.
Material changes and management commentary
- Gross margin improved mainly because of a greater sales mix of higher-margin Food Safety diagnostic products, plus stronger Animal Safety sales of rodenticides and small-animal supplements.
- Operating expenses rose due to personnel and infrastructure investments, higher legal and professional fees—largely related to intellectual-property protection—and increased research and development project costs.
- Food Safety growth included higher natural-toxin testing sales amid a U.S. aflatoxin outbreak following unusually hot, dry weather, and increased allergen testing sales. Management said the new ANSR pathogen detection system could benefit sales in the second half of the fiscal year, with potential customers then evaluating it.
- Animal Safety growth reflected rodenticide sales and DNA testing. GeneSeek revenue increased 19.5%, including Igenity; excluding Igenity, GeneSeek growth was 12.1%. Lower racing-market testing affected Life Science and Other sales, while veterinary instruments and other sales reflected lost business from a large customer.
Outlook, risks, and contingencies
Neogen does not provide forecasts of future performance. Management expressed optimism about long-term prospects and stated that cash, marketable securities, available credit, and expected operating cash flow should fund activities for the foreseeable future. It cautioned that these resources might not cover planned product commercialization or acquisitions, and that equity or other financing could be considered.
Disclosed risks include competition; recruiting and retaining key employees; weather effects on agriculture and food production; acquisition identification and integration; research and development; intellectual-property protection; regulation; foreign-exchange exposure; and weaker economic conditions in foreign markets. The company uses derivatives to manage some currency exposure, primarily involving the U.S. dollar, British pound, and euro.
The company reported an estimated $916,000 liability for environmental remediation and monitoring at its Randolph, Wisconsin facility, expected to be incurred over an estimated 15-year period; annual costs over the prior five years ranged from $50,000 to $105,000. Management said ordinary-course legal and other proceedings were not expected to materially affect results or financial position. The remaining GeneSeek contingent consideration liability was $1.408 million, with payment expected in Q4 FY2013. Management said adoption of the discussed accounting updates was not expected to materially affect the financial statements.
Important facts for investors to verify
- Whether Food Safety growth and the favorable product mix—and the weather-related aflatoxin testing demand in particular—persist beyond this quarter.
- Whether the ANSR product and the integration of Igenity produce the revenue growth management anticipates, and how acquisition-related costs or payments develop.
- Whether expense growth moderates after the personnel, infrastructure, legal, and R&D increases, and whether margin improvements continue.
- Whether operating cash generation remains adequate as receivables, commercialization spending, and potential acquisitions affect liquidity; verify any future financing needs.
- Progress and cash costs of the Wisconsin remediation, the final GeneSeek contingent payment, and any material developments in legal or other proceedings.